Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

被引：0
|
作者：
F Passamonti
B Mora
T Giorgino
P Guglielmelli
M Cazzola
M Maffioli
A Rambaldi
M Caramella
R Komrokji
J Gotlib
J J Kiladjian
F Cervantes
T Devos
F Palandri
V De Stefano
M Ruggeri
R Silver
G Benevolo
F Albano
D Caramazza
E Rumi
M Merli
D Pietra
R Casalone
T Barbui
L Pieri
A M Vannucchi
机构：
[1] University of Insubria,Division of Hematology, Department of Clinical and Experimental Medicine
[2] Ospedale di Circolo,Department of Experimental and Clinical Medicine
[3] ASST Sette Laghi,Department of Oncology and Hematology
[4] Institute of Neurosciences,Department of Hematology and BMT Unit
[5] National Research Council of Italy,Malignant Hematology Department
[6] CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproloiferative,Division of Hematology
[7] Azienda ospedaliera-Universitaria Careggi,Department of Hematology
[8] University of Florence,Department of Oncology and Hematology
[9] Università di Pavia,Department of Oncology and Hematology
[10] University of Milan,Department of Services
[11] ASST Papa Giovanni XXIII,undefined
[12] Department of Oncology and Hematology Ospedale Niguarda Cà Granda,undefined
[13] Moffit Cancer Center,undefined
[14] Stanford University,undefined
[15] Hôpital Saint-Louis et Université Paris Diderot,undefined
[16] Hospital Clínic,undefined
[17] IDIBAPS,undefined
[18] University of Barcelona,undefined
[19] University Hospitals Leuven,undefined
[20] Policlinico S. Orsola-Malpighi,undefined
[21] Institute of Hematology,undefined
[22] Università Cattolica del Sacro Cuore,undefined
[23] Ospedale S. Bortolo,undefined
[24] Weill Cornell Medical College,undefined
[25] Centro Oncologico Ematologico Subalpino (COES),undefined
[26] Department of Oncology and Hematology Università di Bari,undefined
[27] Cytogenetics and Medical Genetics Laboratory,undefined
[28] Ospedale di Circolo,undefined
[29] ASST Sette Laghi,undefined
来源：
Leukemia | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：970 / 973
页数：3
相关论文
共 50 条
  • [31] MULTICENTER STUDY OF PATIENTS WITH MUTATIONS IN GENES POTENTIALLY CAUSING HYPERCALCEMIA
    Arango Sancho, Pedro
    Madariaga Dominguez, Leyre
    Ortega, Pedro J.
    Gonzalez Rodriguez, Juan David
    Aparicio Lopez, Cristina
    De Lucas Collantes, Carmen
    Blazquez Gomez, Cristina
    Angeles Fernandez, Ma
    Herrero Goni, Maria
    Fraga Rodriguez, Gloria Ma
    Espino Hernandez, Maria Del Mar
    Garcia Nieto, Victor Manuel
    PEDIATRIC NEPHROLOGY, 2023, 38 : S252 - S253
  • [32] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Cervantes, Francisco
    Dupriez, Brigitte
    Pereira, Arturo
    Passamonti, Francesco
    Reilly, John T.
    Morra, Enrica
    Vannucchi, Alessandro M.
    Mesa, Ruben A.
    Demory, Jean-Loup
    Barosi, Giovanni
    Rumi, Elisa
    Tefferi, Ayalew
    BLOOD, 2009, 113 (13) : 2895 - 2901
  • [33] Does fibrosis persist after allogeneic HSCT in patients with myelofibrosis, who are otherwise negative for driver mutations, with full donor chimerism?
    Sora, F.
    Chiusolo, P.
    Laurenti, L.
    Giammarco, S.
    Innocenti, I.
    Metafuni, E.
    Autore, F.
    Galli, E.
    Sica, S.
    Bacigalupo, A.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 330 - 330
  • [34] SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)
    Zhao, Lin-Pierre
    De Oliveira, Rafael Daltro
    Marcault, Clemence
    Soret, Juliette
    Gauthier, Nicolas
    Verger, Emmanuelle
    Maslah, Nabih
    Roux, Blandine
    Parquet, Nathalie
    Dosquet, Christine
    Rea, Delphine
    Zini, Jean-Marc
    Vainchenker, William
    Raffoux, Emmanuel
    Giraudier, Stephane
    Cassinat, Bruno
    Kiladjian, Jean-Jacques
    Benajiba, Lina
    BLOOD, 2020, 136
  • [35] IMPACT OF DRIVER AND HIGH MOLECULAR RISK MUTATIONS ON CLINICAL PHENOTYPE AND PROGNOSIS IN PATIENTS WITH POST-POLYCYTHEMIA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN AGIMM STUDY
    Rotunno, G.
    Pacilli, A.
    Guglielmelli, P.
    Brogi, G.
    Artusi, V.
    Rumi, E.
    Delaini, F.
    Mannarelli, C.
    Biamonte, F.
    Maffioli, M.
    Fjerza, R.
    Pieri, L.
    Pietra, D.
    Belotti, C.
    Bosi, A.
    Tagliafico, E.
    Manfredini, R.
    Bernardis, I.
    Passamonti, F.
    Rambaldi, A.
    Barbui, T.
    Cazzola, M.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 44 - 45
  • [36] Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
    Paz, Damien Luque
    Riou, Jeremie
    Verger, Emmanuelle
    Cassinat, Bruno
    Chauveau, Aurelie
    Ianotto, Jean-Christophe
    Dupriez, Brigitte
    Boyer, Francoise
    Renard, Maxime
    Mansier, Olivier
    Murati, Anne
    Rey, Jerome
    Etienne, Gabriel
    Mansat-De Mas, Veronique
    Tavitian, Suzanne
    Nibourel, Olivier
    Girault, Stephane
    Le Bris, Yannick
    Girodon, Francois
    Ranta, Dana
    Chomel, Jean-Claude
    Cony-Makhoul, Pascale
    Sujobert, Pierre
    Robles, Margot
    Ben Abdelali, Raouf
    Kosmider, Olivier
    Cottin, Laurane
    Roy, Lydia
    Sloma, Ivan
    Vacheret, Fabienne
    Wemeau, Mathieu
    Mossuz, Pascal
    Slama, Borhane
    Cussac, Vincent
    Denis, Guillaume
    Walter-Petrich, Anouk
    Burroni, Barbara
    Jezequel, Nathalie
    Giraudier, Stephane
    Lippert, Eric
    Socie, Gerard
    Kiladjian, Jean-Jacques
    Ugo, Valerie
    BLOOD ADVANCES, 2021, 5 (05) : 1442 - 1451
  • [37] Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
    V Panagiota
    F Thol
    B Markus
    B Fehse
    H Alchalby
    A Badbaran
    U Lehmann
    C Koenecke
    R Shahswar
    A Chaturvedi
    M Stadler
    M Eder
    G Göhring
    M Koenigsmann
    A Kloos
    A Trummer
    T Schroeder
    G Kobbe
    C Thiede
    U Platzbecker
    B Schlegelberger
    H-H Kreipe
    A Ganser
    N Kröger
    M Heuser
    Leukemia, 2014, 28 : 1552 - 1555
  • [38] Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
    Panagiota, V.
    Thol, F.
    Markus, B.
    Fehse, B.
    Alchalby, H.
    Badbaran, A.
    Lehmannt, U.
    Koenecke, C.
    Shahswar, R.
    Chaturvedi, A.
    Stadler, M.
    Eder, M.
    Goehring, G.
    Koenigsmann, M.
    Kloos, A.
    Trummer, A.
    Schroeder, T.
    Kobbe, G.
    Thiede, C.
    Platzbecker, U.
    Schlegelbergers, B.
    Kreipe, H-H
    Ganser, A.
    Kroeger, N.
    Heuser, M.
    LEUKEMIA, 2014, 28 (07) : 1552 - 1555
  • [39] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    International Journal of Hematology, 2017, 105 : 309 - 317
  • [40] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Komatsu, Norio
    Kirito, Keita
    Shimoda, Kazuya
    Ishikawa, Takayuki
    Ohishi, Kohshi
    Ohyashiki, Kazuma
    Takahashi, Naoto
    Okada, Hikaru
    Amagasaki, Taro
    Yonezu, Toshio
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 309 - 317
12345